Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Profit After Tax (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Profit After Tax readings, the most recent being -$10.0 million for Q1 2026.

  • Quarterly Profit After Tax fell 29.75% to -$10.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$35.1 million through Mar 2026, down 29.97% year-over-year, with the annual reading at -$32.8 million for FY2025, 34.18% down from the prior year.
  • Profit After Tax hit -$10.0 million in Q1 2026 for DiaMedica Therapeutics, down from -$8.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$3.1 million in Q3 2022 and bottomed at -$10.0 million in Q1 2026.
  • Average Profit After Tax over 5 years is -$5.9 million, with a median of -$5.2 million recorded in 2023.
  • The largest annual shift saw Profit After Tax rose 11.33% in 2022 before it plummeted 53.07% in 2024.
  • DiaMedica Therapeutics' Profit After Tax stood at -$3.8 million in 2022, then tumbled by 37.59% to -$5.2 million in 2023, then plummeted by 53.07% to -$7.9 million in 2024, then fell by 11.06% to -$8.8 million in 2025, then dropped by 13.97% to -$10.0 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Profit After Tax are -$10.0 million (Q1 2026), -$8.8 million (Q4 2025), and -$8.6 million (Q3 2025).